Anti-IgE and chemotherapy: A critical appraisal of treatment options for severe asthma
Walters, H., Walters, J. AE., & Wood-Baker, R. (2007). Anti-IgE and chemotherapy: A critical appraisal of treatment options for severe asthma. Expert Opinion on Pharmacotherapy, 8(5), 585-592. doi:10.1517/146565184.108.40.2065
In this narrative review the scientific rationale for the development of a therapeutic modality for asthma based on decreasing the circulating and cell-bound levels of immunoglobulin-E (IgE) is outlined. The one drug that has so far entered clinical practice to do this is a humanised monoclonal antibody to the Fc portion of the IgE molecule, omalizumab. It is highly effective in reducing IgE blood levels and its established mode of delivery is by subcutaneous injection. The clinical trial development of omalizumab is reviewed and the published data and claims for its efficacy and role in clinical practice is critically appraised. The target group of omalizumab has become focused on severe asthmatics who are still symptomatic after being administered with high-dose inhaled corticosteroids plus long-acting β-agonists. The strongest evidence for effect is in those with frequent severe exacerbations.